Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $330 from $328 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen announces FDA approval of Uplizna
- Amgen’s Strong Market Position and Growth Potential Justify Buy Rating
- Senator Slams Pfizer (PFE) for “Biggest Tax-Dodging Scheme in Pharma History”
- Quantinuum Shakes Up Quantum Computing with Giant Backers and Big Moves
- Cathie Wood’s ARK Invest Snaps Up Tesla Stock (TSLA) amid 42% Price Drop